Science AdvancesMicrobiologyPeer-reviewed journal article
A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo
Gregory MatheziD, Paulo Jacob SilvaiD, Vincent Carlen, Charlotte Deloizy, Clémentine Prompt, Anaïs HubartiD, Joana Rocha‐PereiraiD, Marie GallouxiD, Ronan Le GofficiD, Francesco StellacciiD, Valeria CagnoiD
Abstract
Respiratory viruses can cause severe infections, including bronchiolitis and pneumonia, often leading to hospitalization or death. Due to their ease of transmission, they are also scrutinized for their pandemic potential. No broad-spectrum antiviral is currently available. However most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized and characterized a unique modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This novel compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, SARS-CoV-2. Additionally, the compound is active against different avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad- spectrum activity in ex vivo models of respiratory tissues and in vivo experiments against RSV and Influenza virus, using both prophylactic and therapeutic strategies. These findings represent a significant step forward in the development of future treatments and preventive measures for respiratory viral infections. Significance StatementFollowing the SARS-CoV-2 pandemic, Influenza A H5N1 has become widespread in poultry and has already begun to spill over into mammals, posing a potential risk for the next pandemic. Indeed, respiratory viruses represent a major threat for future global health crises. Unfortunately, there is a significant lack of broad-spectrum antivirals available for such scenarios. To address this gap, our study developed a single molecule with the capacity to inhibit a wide range of clinically relevant human respiratory viruses including avian strains of influenza virus. This antiviral demonstrated verified efficacy not only in cellular systems but also in human-derived respiratory tissues and animal models.
- organism: human
- organism: mouse
- research focus: drug response / drug discovery
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 7
- FWCI
- 4.82
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of Broad-spectrum β-cyclodextrins-Based Nanomaterials Against Influenza Viruses
A. C.-A. Zwygart, C. Medaglia, … C. Tapparel·bioRxiv·Mar 5, 2024
- A natural broad-spectrum inhibitor of enveloped virus entry, effective against SARS-CoV-2 and Influenza A Virus in preclinical animal models.
R. Narayan, M. Sharma, … S. Tripathi·bioRxiv·Feb 16, 2022
- Deconstructing natural products to develop synthetic small molecule attachment inhibitors with broad spectrum antiviral activity
Consuelo C Correa-Sierra, Jody Cameron, … Luis M. Schang·bioRxiv·May 20, 2025
- Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
R. Rathnasinghe, M. Salvatore, … A. Garcia-Sastre·bioRxiv·Apr 28, 2021
- Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity
U. Rand, S. Y. Kupke, … D. Bruder·bioRxiv·Feb 19, 2021
- Non-Toxic Virucidal Macromolecules Show High Efficacy Against Influenza Virus Ex Vivo and In Vivo
O. Kocabiyik, V. Cagno, … F. Stellacci·bioRxiv·Mar 18, 2020